Immunotherapy with chemotherapy for locally advanced stomach cancer
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial studies toripalimab (an immune system medicine) plus FLOT chemotherapy in people with stomach cancer that has grown locally but hasn’t spread to distant organs. It aims to improve control of the cancer and help more people have their tumors fully treated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old (any gender).
- Your stomach cancer is confirmed as adenocarcinoma by pathology (biopsy/surgery tissue test).
- The cancer has not spread to distant organs, and your surgeons think it can be removed (or might be able to be removed).
- You have an ECOG performance status of 0 or 1, meaning you’re able to care for yourself and do light activity.
- Your tumor test shows PD-L1 CPS is 1 or higher.
- You must have enough heart, liver, kidney, and blood function for treatment, and you can be on stable medications for blood pressure or diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (QL1706) to a standard chemotherapy regimen, given before surgery, can help shrink stomach or gastroesophageal junction cancer. The goal is to improve the chance of successful surgery and long-term outcomes.
This trial tests a combination of two immunotherapy drugs plus chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach helps shrink tumors and improve survival compared to standard treatment.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of the immunotherapy drug pembrolizumab with chemotherapy (FLOT) for people with advanced stomach or gastroesophageal junction cancer. It may help if your cancer has not been treated before and you are in reasonably good health.
This Phase 2 study tests whether combining two medicines—anlotinib and toripalimab—can work well as first treatment for advanced (stage IV) stomach cancer. It’s meant for people who have an adequate overall health status and certain blood/organ function levels.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and targeted radiation for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this approach helps shrink tumors or slow the disease.
Hear when a new Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.